AZD4547

目录号:S2801

AZD4547 Chemical Structure

Molecular Weight(MW): 463.57

AZD4547是一种新型选择性的FGFR抑制剂,靶向作用于FGFR1/2/3,在无细胞试验中IC50为0.2 nM/2.5 nM/1.8 nM,对FGFR4, VEGFR2(KDR)具有微弱的作用活性,对IGFR, CDK2和p38几乎没有作用活性。Phase 2/3。

规格 价格 库存 购买数量  
RMB 1801.43 现货
RMB 901.31 现货
RMB 1395.39 现货
RMB 4661.52 现货
RMB 7125.05 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献25篇:

产品安全说明书

FGFR抑制剂选择性比较

生物活性

产品描述 AZD4547是一种新型选择性的FGFR抑制剂,靶向作用于FGFR1/2/3,在无细胞试验中IC50为0.2 nM/2.5 nM/1.8 nM,对FGFR4, VEGFR2(KDR)具有微弱的作用活性,对IGFR, CDK2和p38几乎没有作用活性。Phase 2/3。
特性 AZD4547高选择性作用于 FGFR1-3,比作用于FGFR4选择性高。AZD4547有效作用于野生型和突变型FGFR酪氨酸激酶活性。
靶点
FGFR1 [1]
(Cell-free assay)
FGFR3 [1]
(Cell-free assay)
FGFR2 [1]
(Cell-free assay)
KDR [1]
(Cell-free assay)
0.2 nM 1.8 nM 2.5 nM 24 nM
体外研究

与 FGFR1-3相比, AZD4547作用于FGFR4,活性微弱,IC50为165 nM。AZD4547 只抑制重组 VEGFR2 (KDR) 激酶活性, IC50为 24 nM,在体外选择性作用于一组多种代表性的人类激酶。0.1 μM AZD4547 作用于一系列重组激酶,包括 ALK, CHK1, EGFR, MAPK1, MEK1, p70S6K, PDGFR, PKB, Src, Tie2,和 PI3K,没有作用活性。相应地,在细胞磷酸化实验中,可观察到AZD4547 作用于FGFR1-3的选择性比作用于 FGFR4, IGFR, 和 KDR高。AZD4547在体外,只有作用于表达去调控FGFRs 如KG1a, Sum52-PE,和KMS11的肿瘤细胞,具有有效抗增殖活性,IC50 为18-281 nM,而对MCF7 及100 种以上其他肿瘤细胞无活性。AZD4547 处理人类肿瘤细胞,有效抑制FGFR 和 MAPK 磷酸化,这种作用存在剂量依赖性。AZD4547 也有效抑制FRS2 和 PLCγ磷酸化,及下游FGFR信号。另外, AZD4547作用于乳腺细胞系,MCF7和Sum52-PE 而不是KG1a和 KMS11细胞,影响AKT磷酸化。AZD4547处理Sum52-PE 和 KMS11细胞,显著诱导凋亡,作用于KG1a细胞,显著提高细胞周期在G1期停滞而不是凋亡, 而作用于MCF7细胞,对细胞周期分布和凋亡都没有作用效果。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SNU449 M33CfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fDS|czKGh? MYrJR|UxRTBwMEiyJO69VQ>? M4jKd|I3OzVzM{Kw
SK-HEP-1 NXvZZpE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fJdlczKGh? MoHxTWM2OD1yLkC4OEDPxE1? NVHiOndtOjZ|NUGzNlA>
SNU475 MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWK3NkBp NYW5UI9LUUN3ME21MlQh|ryP NInuTZczPjN3MUOyNC=>
Hep3B MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvaZlU4OiCq MVjJR|UxRTZwNEOg{txO MVOyOlM2OTN{MB?=
PLC/PRF5 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fNW|czKGh? MlPwTWM2OD14LkW1JO69VQ>? NGjEd|kzPjN3MUOyNC=>
Hur7 NX\TNXd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rucVczKGh? MonrTWM2OD15LkK1JO69VQ>? NYHkW2xXOjZ|NUGzNlA>
HepG2 NIX1eGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXToS5ZbPzJiaB?= NVW5PWlsUUN3ME24Mlc{KM7:TR?= NFuzUGgzPjN3MUOyNC=>
SNU449 NILWb3VEdG:wb3flcolkKGG|c3H5 M1vGR|EhyrWP M1HCXVI1KGh? NFjwfnBl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7 M1vTclI3OzVzM{Kw
SK-HEP-1 NEW5Zm5EdG:wb3flcolkKGG|c3H5 NV\2[mc6OSEEtV2= NX74XWdROjRiaB?= M3fXTIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHl? MUGyOlM2OTN{MB?=
SNU449 NUHo[mQ1TnWwY4Tpc44hSXO|YYm= M1:zb|AuOiEQvF2= M4PjWFQ5KGh? MWLjZZV{\XNiYTDk[YNz\WG|ZTDv[kBHWlN{78{MRWtVNCCjbnSgSXJMKHCqb4PwbI9zgWyjdHnvci=> NULJR3FoOjZ|NUGzNlA>
SK-HEP-1 MYfGeY5kfGmxbjDBd5NigQ>? NXXISYhDOC1{IN88US=> MV60PEBp NVHxZ|Bb[2G3c3XzJIEh\GWlcnXhd4Uhd2ZiRmLTNw+9lEGNVDygZY5lKEWUSzDwbI9{eGixconsZZRqd25? NHLiTI0zPjN3MUOyNC=>
BaF3 FLT3-TEL MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fqW2dKPTB;ND62JOKyKDBwNUe3JO69VQ>? MXqyOlI6PDd2MR?=
BaF3 RET-TEL NXnwemxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf0OIIzT0l3ME2wMlM6KMLzIECuNFQ5KM7:TR?= NEfVW3AzPjJ7NEe0NS=>
BaF3 Parental MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;oTGdKPTExubWxNEDPxE1? NV3TSXA1OjZ{OUS3OFE>
MOLM14 FLT3/ITD MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojyS2k2OD1yLkS4OEDDuSByLkG1O{DPxE1? NW[2RlFXOjZ{OUS3OFE>
MV4-11 FLT3/ITD NHrDUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\HTVUxRTBwNEW5JOKyKDBwMES2JO69VQ>? M1HnfVI3Ojl2N{Sx
TT RET C634W NX7RV|JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn0S2k2OD1{LkmgxtEhOC57MESg{txO M33TfVI3Ojl2N{Sx
AN3-CA FGFR2 N550K, K310R M2PJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi2S2k2OD1yLkCzNUDDuSByLkCyN{DPxE1? M3XBO|I3Ojl2N{Sx
MFE296 FGFR2 N550K MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfx[|dIUTVyPUCuO|MxKMLzIECuNFU4KM7:TR?= NXTJXXI{OjZ{OUS3OFE>
MFE280 FGFR2 S252W MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\pS2k2OD1yLkKxPEDDuSByLkC3N{DPxE1? NIDRb4kzPjJ7NEe0NS=>
Ishikawa FGFF2 over exp. MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPRS2k2OD12LkWgxtEhOS53MTFOwG0> MnzzNlYzQTR5NEG=
HEC1A Normal FGFR2 M3Lw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXlO2tXT0l3MP-5qVExKM7:TR?= MYGyOlI6PDd2MR?=
A549 NWCxbJB1S2WubDD2bYFjcWyrdImgRZN{[Xl? MW[wMlEwOSEQvF2= M3vOclQ5KGh? M2XzUIVvcGGwY3XzJGVzdG:2aX7pZkBqdmS3Y3XkJJZq[WKrbHn0fUBtd3O| NXy5UHU4OjZyNUOwNlA>
SGC-7901 M3Oxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rMTVEhdk1vMUCg{txO NWHqWnJWPzJiaB?= NIHQbHBKSzVyIH;mJFUuOTBizszNMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M3W1NlI2PTd4OUG1
HGC-27 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3jNUBvVS1zMDFOwG0> NHjnfGo4OiCq MoSxTWM2OCCxZjC1MVExKM7:TTygbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NXe5eVlsOjV3N{[5NVU>
MKN-28 M{f4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGxJI5ONTFyIN88US=> MkjyO|IhcA>? NIPzTFFKSzVyIH;mJFUuOTBizszNMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NXPPOm1YOjV3N{[5NVU>
NCI-N87 M4nGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTkR3AzOSCwTT2xNEDPxE1? NIiyXXI4OiCq MWrJR|UxKG:oIEWtNVAh|ryPLDDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MljGNlU2PzZ7MUW=
KATOIII NFTyNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXZNUBvVS1zMDFOwG0> MkDJO|IhcA>? MkHxTWM2OCCxZjCxNE0yODBibl2sJIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NIPFc2MzPTV5NkmxOS=>
SNU-16 MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrid2tyOSCwTT2xNEDPxE1? MVy3NkBp M{fUS2lEPTBib3[gNVAuOTByIH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NVjTSGZUOjV3N{[5NVU>
4T1 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HrdWlEPTB;MD62OOKyOC5zMTFOwG0> NV;FfJpkOjR4NEK4PVM>
MDA-MB-468 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTRwOdMxNE45PSEQvF2= M4TaSlI1PjR{OEmz
HCT116 NFfPWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzwT4I6UUN3ME2xOU46yrFzLkiyJO69VQ>? MWWyOFY1Ojh7Mx?=
SW620 M3Hx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|Ux97zgMkCg{txO M1zIdFI1PjR{OEmz
MDA-MB-231 NWnzWmtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|Ux97zgMkCg{txO MWCyOFY1Ojh7Mx?=
CT26 NYDmUY5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTUTWM2OO,:nkKwJO69VQ>? NHnucYUzPDZ2Mki5Ny=>
SW480 M3iycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13VOGlEPTExvK6yNEDPxE1? NU\TdId3OjR4NEK4PVM>
4T1 NFe1WIRCeG:ydH;zbZMhSXO|YYm= Ml\qNU4zPS1{MDFOwG0> NFnNbIozPCCq MnT1bY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NH7xRWkzPDZ2Mki5Ny=>
KG1a Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Xs[WlEPTB;MD6wNVgh|ryP Mlq2NlI{Pjl7Mki=
Sum52-PE M4X1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMESxJO69VQ>? MoDmNlI{Pjl7Mki=
KMS11 NIXBWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7ETWM2OD1yLkK4NUDPxE1? NFHIbWQzOjN4OUmyPC=>
MCF7 M1LnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRjNyIN88US=> MoH5NlI{Pjl7Mki=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-FGFR / FGFR1 / p-AKT / AKT / p-ERK / ERK; 

PubMed: 28900173     


Western blots (cropped) are shown for the indicated proteins in MDA-MB-361, BT474, and SKBR3 cells treated with AZD4547 (0, 1, 3, or 5 µM) for 72 hours. 

pFRS2; 

PubMed: 25576915     


AZD4547 inhibits FGFR2 pathway activation in SNU16 and KATOIII cells. Cells were incubated with AZD4547 at the indicated doses. Cell lysates were immunoblotted for phospho-FGFR, phospho-FRS2, phospho- and total AKT, and phospho- and total ERK.

28900173 25576915
Growth inhibition assay
Cell viability; 

PubMed: 28900173     


MDA-MB-361, BT474, and SKBR3 ErbB2-overexpressing breast cancer cells were treated with AZD4547 (0, 0.1, 0.3, 1, 3, or 5 µM) for 5 days. Then the viable fraction of each cell line was determined with an MTS assay. 

Cell viability; 

PubMed: 25576915     


FGFR2-amplified GC cells are selectively sensitive to AZD4547. In vitro CCK-8 assay across a panel of 6 GC cells demonstrated that SNU16 and KATOIII cells were extremely sensitive to AZD4547 with IC50 values of 5-10 nM. Data (n = 6) are presented as mean ± SD.

28900173 25576915
体内研究 AZD4547按3 mg/kg剂量口服处理携带KMS11肿瘤的小鼠,每天两次,与空白对照组相比,显著抑制53%肿瘤生长,AZD4547 按 12.5 mg/kg剂量每天处理一次,或按 6.25 mg/kg剂量每天处理两次,则完全抑制肿瘤,这与p-FGFR3的药效学调节剂量正相关,且降低 KMS11肿瘤细胞增殖。而且, AZD4547按 12.5 mg/kg剂量口服处理给药FGFR1融合KG1a 移植瘤模型,每天一次,抑制65% 肿瘤生长。在有效剂量水平,AZD4547不表现出抗血管生成的效果。AZD4547 对血压没有显著作用效果,因此在体内缺乏 抗-KDR 活性。相应地, AZD4547按6.25 mg/kg剂量口服处理对Cediranib敏感的移植瘤模型,包括 Calu-6, HCT-15 和 LoVo,每天两次,没有作用活性。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

AZD4547 激酶活性:

使用浓度等于或低于相对Km 的ATP,测定AZD4547抑制 FGFR1-3的人类重组激酶活性的效果。
细胞实验:[1]
+ 展开
  • Cell lines: KG1a, Sum52-PE, KMS11, 和MCF7
  • Concentrations: 溶于DMSO,终浓度为 ~1 μM
  • Incubation Time: 72 小时
  • Method: 使用多种浓度AZD4547处理细胞72小时。通过 MTS 增殖实验获得抗增殖的IC50值。荧光激活细胞分选(FACS)中,细胞与70%乙醇混合,然后与碘化丙啶/RNase A标记溶液温育。使用 FACSCalibur 仪器和CellQuest分析软件测定细胞周期谱。为了分析凋亡,轻轻收集细胞和培养基,离心,然后冲洗细胞颗粒。细胞进行Annexin膜联蛋白 V-异硫氰酸荧光素(FITC)染色和碘化丙啶吸收。使用FACSCalibur仪器测定 膜联蛋白 V染色阳性细胞比例,使用CellQuest分析软件进行象限分类。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 皮下注射LoVo, HCT-15, Calu-6, KMS11 或 KG1a的雌性Swiss衍生裸鼠和SCID小鼠
  • Formulation: 在去离子水的 1% (v/v)Tween-80溶液中配制
  • Dosages: 1.5-50 mg/kg
  • Administration: 口服饲喂,每天一次或两次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 92 mg/mL (198.45 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 463.57
化学式

C26H33N5O3

CAS号 1035270-39-3
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02546661 Recruiting Muscle Invasive Bladder Cancer AstraZeneca October 3 2016 Phase 1
NCT02546661 Recruiting Muscle Invasive Bladder Cancer AstraZeneca October 3 2016 Phase 1
NCT02824133 Suspended Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion|Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion Assistance Publique - Hôpitaux de Paris September 2015 Phase 1|Phase 2
NCT02824133 Suspended Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion|Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion Assistance Publique - Hôpitaux de Paris September 2015 Phase 1|Phase 2
NCT02465060 Recruiting Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Ovarian Carcinoma|Pancreatic Carcinoma|Plasma Cell Myeloma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Plasma Cell Myeloma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Carcinoma|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer National Cancer Institute (NCI) August 12 2015 Phase 2
NCT02465060 Recruiting Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Ovarian Carcinoma|Pancreatic Carcinoma|Plasma Cell Myeloma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Plasma Cell Myeloma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Carcinoma|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer National Cancer Institute (NCI) August 12 2015 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

相关FGFR产品

Tags: 购买AZD4547 | AZD4547供应商 | 采购AZD4547 | AZD4547价格 | AZD4547生产 | 订购AZD4547 | AZD4547代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID